Kythera Biopharmaceuticals Announces Second Phase II Clinical Trial With Adipolytic Agent For Reduction Of Submental Fat

You have to be submental to fall for this stuff.

"Kythera Biopharmaceuticals, Inc. ("Kythera") announced the initiation of a second Phase II clinical trial evaluating its proprietary product, ATX-101, for the reduction of unwanted submental (under chin) fat. This clinical trial is the second in a series of Phase II studies of ATX-101 in aesthetic applications and is aimed at assessing the safety and effectiveness of ATX-101 as a 'liposculpting' agent. The clinical program aims to lead to registration of ATX-101 as an approved prescription drug in the U.S., Europe and Asia."

Sounds scientific.

Sounds terrific.

It ain't.

It's craperrific.